The House Energy and Commerce Committee has broadened its investigation of alleged FDA shortcomings to request more information about Actavis recalls, including the August withdrawal of all products from a New Jersey plant. Chairman John Dingell (D-Mich.) and Oversight and Investigations Subcommittee Chairman Bart Stupak (D-Mich.) sent FDA Commissioner Andrew von Eschenbach a letter last week requesting related documents. They cite an Aug. 1 statement in which the FDA said the August recall was limited to products from the Little Falls, N.J., plant (WDL, Aug. 11).
展开▼
机译：众议院能源和商业委员会已扩大了对据称FDA缺陷的调查，要求提供更多有关Actavis召回的信息，包括8月从新泽西州一家工厂撤回所有产品。主席约翰·丁格尔（D-Mich。）和监督与调查小组委员会主席巴特·斯塔帕克（Bart Stupak）（D-Mich。）上周致信FDA专员安德鲁·冯·埃申巴赫（Andrew von Eschenbach），要求提供相关文件。他们援引了8月1日的声明，其中FDA表示8月份的召回仅限于新泽西州Little Falls工厂的产品（WDL，8月11日）。
展开▼
